- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare Tata India Pharma & Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.14 | 1.92 |
NAV | ₹29.46 | ₹37.42 |
Fund Started | 04 Dec 2015 | 25 Jun 2018 |
Fund Size | ₹1208.05 Cr | ₹5024.00 Cr |
Exit Load | Exit load of 0.25% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.14
1.92
NAV
₹29.46
₹37.42
Fund Started
04 Dec 2015
25 Jun 2018
Fund Size
₹1208.05 Cr
₹5024.00 Cr
Exit Load
Exit load of 0.25% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 38.92% | 47.43% |
3 Year | 19.22% | 23.16% |
5 Year | 26.39% | 30.01% |
1 Year
38.92%
47.43%
3 Year
19.22%
23.16%
5 Year
26.39%
30.01%
Holding Analysis
Equity | 94.61% | 97.87% |
Cash | 5.39% | 2.13% |
Equity
94.61%
97.87%
Cash
5.39%
2.13%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.31% |
Aurobindo Pharma Ltd. | 8.57% |
Lupin Ltd. | 7.43% |
Dr. Reddy's Laboratories Ltd. | 6.48% |
Cipla Ltd. | 6.29% |
Divi's Laboratories Ltd. | 5.12% |
Fortis Healthcare Ltd. | 4.42% |
Zydus Lifesciences Ltd. | 3.91% |
Alkem Laboratories Ltd. | 3.60% |
Apollo Hospitals Enterprise Ltd. | 3.42% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 14.35% |
Dr. Reddy's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 8.07% |
Lupin Ltd. | 4.59% |
Aurobindo Pharma Ltd. | 4.57% |
Gland Pharma Ltd. | 4.22% |
Apollo Hospitals Enterprise Ltd. | 3.80% |
Zydus Lifesciences Ltd. | 2.93% |
Divi's Laboratories Ltd. | 2.69% |
Biocon Ltd. | 2.39% |
Fund Manager
Name | Meeta Shetty | Dharmesh Kakkad |
Start Date | 09 Nov 2018 | 23 Feb 2021 |
Name
Meeta Shetty
Dharmesh Kakkad
Start Date
09 Nov 2018
23 Feb 2021
About Fund
Description | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 04 Dec 2015 | 25 Jun 2018 |
Description
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
04 Dec 2015
25 Jun 2018
